The primary endpoint of this study is to determine whether cycles of short term FMD exposure to a fasting-mimicking diet is effective in reducing total cholesterol levels.
Age ≥ 18 years
WHO performance status score 0-2
Early stage breast cancer, ER positive, receiving an adjuvant endocrine treatment with aromatase inhibitor
Hypercholesterolemic (total cholesterol >200mg/dL)
Underweight (BMI < 18.5 kg/m2)
Current or past eating disorders identified with the SCOFF Questionnaire (Useful Eating Disorder screening questions) [19]
Malnutrition Universal Screening Tool (MUST). It considers body mass index, weight change and acute disease effect equally and determines a malnutrition risk score. A score ≥1 identify a patient at moderate risk of malnutrition;
Treatment with any investigational or non-registered drug other than the study product(s) within 30 days preceding the first dose of study product, or planned use during the study period